/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg, a generic version of Ranexa1 Extended-Release Tablets, 500 mg and 1,000 mg, of Gilead Sciences, Inc.
According to IQVIAsales data for the 12 month period ending May 2019, the Ranexa Extended-Release Tablets, 500 mg and 1,000 mg market2 achieved annual sales of approximately $929.0 million*.
Glenmark's current portfolio consists of 158 products authorized for distribution in the U.S. marketplace and 57 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
1 All brand names and trademarks are the property of their respective owners.
2 Market includes brand and all available therapeutic equivalents
* IQVIA National Sales Perspectives: Retail & Non-Retail, May 2019
About Glenmark Pharmaceuticals
Disclaimer: No Business Standard Journalist was involved in creation of this content